

## IMPORTANT

*If you are in any doubt about any of the contents of this document, you should obtain independent professional advice.*



### Chengdu Olymvax Biopharmaceuticals Inc. 成都歐林生物科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

[REDACTED]

Number of [REDACTED] under : [REDACTED] H Shares (subject to  
the [REDACTED] the [REDACTED] and the [REDACTED])  
Number of [REDACTED] : [REDACTED] H Shares (subject to  
[REDACTED] and [REDACTED])  
Number of [REDACTED] : [REDACTED] H Shares (subject to  
[REDACTED], the [REDACTED] and the  
[REDACTED])  
Maximum [REDACTED] : HK\$[REDACTED] per H Share, plus  
brokerage of 1.0%, SFC transaction levy  
of 0.0027%, Stock Exchange trading fee of  
0.00565% and AFRC transaction levy of  
0.00015% (payable in full on application  
in Hong Kong dollars and subject to  
refund)  
Nominal Value : RMB1.00 per H Share  
[REDACTED] : [REDACTED]

Sole Sponsor, [REDACTED]



**CITIC SECURITIES**

[REDACTED]

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

A copy of this document, having attached thereto the documents specified in “Documents Delivered to the Registrar of Companies and Available on Display” in Appendix VII to this document, has been registered by the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission and the Registrar of Companies in Hong Kong take no responsibility as to the contents of this document or any other documents referred to above.

The [REDACTED] is expected to be determined by agreement between the [REDACTED] (for themselves and on behalf of the other [REDACTED]) and the Company on the [REDACTED]. The [REDACTED] is expected to be on or before [REDACTED] (Hong Kong time). The [REDACTED] will be not more than HK\$[REDACTED] per H Share. If, for any reason, the [REDACTED] is not agreed by 12:00 noon on [REDACTED] (Hong Kong time) between the [REDACTED] (for themselves and on behalf of the other [REDACTED]) and the Company, the [REDACTED] will not proceed and will lapse. Applicants for the [REDACTED] may be required to pay, on application (subject to application channels), the maximum [REDACTED] of HK\$[REDACTED] per [REDACTED] together with brokerage of 1.0%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.00565%, subject to refund if the [REDACTED] is less than HK\$[REDACTED] per [REDACTED].

The [REDACTED] (for themselves and on behalf of the other [REDACTED]) may, where considered appropriate and with our consent, reduce the number of H Shares being [REDACTED] under the [REDACTED] and/or the maximum [REDACTED] below that stated in this document at any time on or prior to the morning of the last day for lodging applications under the [REDACTED]. In such a case, an announcement will be published on the websites of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company at [www.olymvax.com](http://www.olymvax.com) as soon as practicable following such decision to make such reduction, and in any event not later than the morning of the day which is the last day for lodging applications under the [REDACTED]. For further details, see “Structure of the [REDACTED]” and “How to Apply for [REDACTED]” in this document.

Prior to making an investment decision, prospective investors should carefully consider all the information set out in this document, including but not limited to the risk factors set out in “Risk Factors” in the document.

The obligations of the [REDACTED] under the [REDACTED] are subject to termination by the [REDACTED] (for itself and on behalf of the [REDACTED]) if certain grounds arise prior to 8:00 a.m. on the [REDACTED]. For more details, see “[REDACTED] — [REDACTED] and Expenses — [REDACTED] — Grounds for Termination” in this document.

The [REDACTED] have not been and will not be registered under the U.S. Securities Act or any state securities laws of the United States and may not be offered or sold within or to the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The [REDACTED] are being offered and sold outside the United States in offshore transactions in accordance with Regulation S.

[REDACTED]

[REDACTED]

**IMPORTANT**

[REDACTED]

## IMPORTANT

---

[REDACTED]